Literature DB >> 19165647

Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease.

X Hua1, J Su, E Svenungsson, E Hurt-Camejo, K Jensen-Urstad, B Angelin, P Båvenholm, J Frostegård.   

Abstract

OBJECTIVE: This study focused on lipoprotein composition and properties in systemic lupus erythematosus (SLE).
METHODS: The size distribution of plasma lipoproteins was studied by nuclear magnetic resonance (NMR). Cholesteryl ester transfer protein (CETP) activity was determined by enzyme-linked immunosorbent assay (ELISA). The affinity of low density lipoprotein (LDL) for proteoglycans was assayed. Twenty-six women (aged 52+/-8.2 years) with SLE and a history of cardiovascular disease (CVD) (SLE cases) were compared with 26 age-matched women with SLE and without CVD (SLE controls) and 26 age-matched population-based control women (controls).
RESULTS: Very low density lipoprotein (VLDL) particles (nmol/L) were more prevalent among SLE cases than SLE controls (0.039) and tended to be more common in SLE cases than in controls (p = 0.073). By contrast, high density lipoprotein (HDL) particles (nmol/L) were more prevalent among controls than SLE cases (p = 0.024) whereas the number of LDL particles (nmol/L) did not differ significantly. Small dense (sd)LDL (nmol/L) were more common in controls and tended to be more common in SLE cases than in SLE controls (p = 0.036 and 0.086, respectively). Small high density lipoproteins (sHDL) (nmol/L) were more prevalent in controls than in SLE controls and SLE cases (p = 0.002 and p<0.001, respectively). VLDL or LDL size (nm) did not differ significantly between groups (data not shown) whereas HDL size (nm) was increased among SLE controls as compared to controls (p = 0.024) and tended to be increased among SLE cases as compared to controls (p = 0.070). The affinity of LDL for proteoglycans or CETP activity did not differ between groups (data not shown).
CONCLUSIONS: sdLDL was not increased and SLE cases and SLE controls had decreased levels of sHDL. VLDL differentiates between SLE cases and SLE controls. The lipid pattern in SLE-related CVD was thus not similar to the pattern seen in diabetes or in CVD in general.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165647     DOI: 10.1080/03009740802541470

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  10 in total

1.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

2.  Management of cardiovascular complications in systemic lupus erythematosus.

Authors:  Carly Skamra; Rosalind Ramsey-Goldman
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

Review 3.  Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk.

Authors:  George A Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  Front Med (Lausanne)       Date:  2022-05-31

Review 4.  HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases.

Authors:  Fabrizia Bonacina; Angela Pirillo; Alberico L Catapano; Giuseppe D Norata
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

5.  Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus.

Authors:  Samuel O Olusi; Sunila George
Journal:  Vasc Health Risk Manag       Date:  2011-02-15

6.  Dyslipidaemia in rheumatological autoimmune diseases.

Authors:  Tracey E Toms; Vasileios F Panoulas; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2011-02-24

7.  CRP Serum Levels Are Associated with High Cardiometabolic Risk and Clinical Disease Activity in Systemic Lupus Erythematosus Patients.

Authors:  Karen Pesqueda-Cendejas; Isela Parra-Rojas; Paulina E Mora-García; Margarita Montoya-Buelna; Adolfo I Ruiz-Ballesteros; Mónica R Meza-Meza; Bertha Campos-López; Melissa Rivera-Escoto; Barbara Vizmanos-Lamotte; Sergio Cerpa-Cruz; Ulises de la Cruz-Mosso
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

Review 8.  Cardiovascular Complications in Systemic Lupus Erythematosus.

Authors:  Rahmah Alghareeb; Afshan Hussain; Marvi V Maheshwari; Nabeeha Khalid; Pragnesh D Patel
Journal:  Cureus       Date:  2022-07-08

Review 9.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

10.  High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus.

Authors:  Krisztina Gaál; Tünde Tarr; Hajnalka Lőrincz; Viktor Borbás; Ildikó Seres; Mariann Harangi; Péter Fülöp; György Paragh
Journal:  Lipids Health Dis       Date:  2016-03-22       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.